Previous 10 | Next 10 |
Summary This is the first 2023 update on the long-term value portfolios consistently beating the S&P 500 since inception with S&P 500 +3.40%, DJIA -2.0% YTD. For 2023 the Piotroski-Graham value portfolio is up 15.0%, Negative Forensic Portfolio is up 11.5%, and Positive Fo...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023. The Company will h...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Christine Silverstein to its Board of Directors and Audit Committee. “Ms. Silverstein brings ...
RBC Capital Markets has initiated Marinus Pharmaceuticals ( NASDAQ: MRNS ) with an outperform rating saying that the launch of Ztalmy (ganaxolone) has been going well and will do even better with additional indications. The firm has a price target of $23 (341% upside based on Thursday...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and preliminary U.S. ZTALMY ® net product revenue for the fourth quarter and year ended Decembe...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 Ame...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Cha...
Collaboration leverages Tenacia’s CNS, R&D, and local market expertise to support expansion of ganaxolone’s development programs and potentially provide additional access to patients globally Marinus to receive an upfront fee of $10 million and eligible t...
Penny Stocks With Unusual Options Activity When it comes to trading penny stocks, options usually don’t initially come to mind for new traders. Most new traders will choose to buy options because higher-priced stocks are too expensive. The options contracts are much cheaper. ...
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Sasha Damouni Ellis – Vice President-Corporate Affairs and Investor Relations Scott Braunstein – Chief Executive Officer Christy S...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...